CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Jupiter Neurosciences (JUNS) set to begin trading Tuesday

By Andrew Knoll

23:07, 17 January 2022

Human head shaped puzzle with one piece missing
Jupiter's once-daily pill offers promise as a potential treatment for Alzheimer’s disease - Photo: Shutterstock

A holiday-shortened week in the US nonetheless figures to provide some intrigue in the IPO market, including the launch of Jupiter Neurosciences, which will begin trading on the Nasdaq Composite on Tuesday.

More than three million units will be available, with a price between $5 and $7 each, according to the IPO filing listed with the US Securities and Exchange Commission.

The Florida-based venture is developing drugs to treat neuroinflammation, a common feature in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and other neurodegenerative conditions, including those stemming from traumatic brain injuries.

Flagship product

That drug – JOTROL – remains in clinical trials, but the once-daily pill offers promise as a potential treatment for Alzheimer’s disease. Its active ingredient is resveratrol, a natural polyphenol found in red grapes, which has shown some effectiveness in combating the advancement of Alzheimer’s. JOTROL delivers a “therapeutically effective dose” without causing digestive or stomach issues, the company said in a news release.

JOTROL is the most advanced drug in Jupiter’s pipeline.

Jupiter obtained a patent for it in 2020, then rebranded in September of 2021 and made additions to its executive team shortly thereafter.

A study published last week demonstrated encouraging results, although US Food and Drug Administration approval still appears further on the horizon.

Broader market potential

The global market for Alzheimer’s disease treatment alone could surpass $25bn (£18.3bn) by 2027, with a robust compound annual growth rate of 17.5%. Alzheimer’s disease is the most common cause of dementia. In the United States, an estimated 5.7 million people are living with Alzheimer’s, a figure that is expected to rise to 14 million by 2050.


15,868.70 Price
+0.420% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8


42,311.00 Price
+0.570% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00


0.62 Price
-1.690% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168


2,021.31 Price
-0.410% 1D Chg, %
Long position overnight fee -0.0200%
Short position overnight fee 0.0118%
Overnight fee time 22:00 (UTC)
Spread 0.50

It is the sixth-leading cause of death in the United States, with a wide array of treatments in various phases of clinical trials, though few efficacious treatments exist beyond those that treat symptoms. Slowing advancement is the primary focus of most drugs in development, as there is no known cure.

More broadly, the neurodegenerative disease treatment market could approach $63bn (£46.2bn) by 2027, albeit with a more modest compound annual growth rate of 7.2%. In addition to the above-mentioned conditions, amyotrophic lateral sclerosis (Lou Gehrig’s disease) and multiple sclerosis are among the most common and nefarious neurodegenerative maladies.

Increased prevalence of such disorders and the strain they have placed on mental health as well as organic health resources have prompted research and investment in treatments, despite relatively limited progress to date.

While the US is expected to dominate the market on both the research and use sides, increasingly favourable conditions in Europe and an outpaced compound annual growth rate in the Pacific Rim will likely contribute to development in those regions as well.

Read more: Reduced US crops send orange juice futures skyward

Related topics

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading